<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Castillero E</submitter><funding>NHLBI NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>eadc9606</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9896655</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(677)</volume><pubmed_abstract>Degenerative mitral valve (MV) regurgitation (MR) is a highly prevalent heart disease that requires surgery in severe cases. Here, we show that a decrease in the activity of the serotonin transporter (SERT) accelerates MV remodeling and progression to MR. Through studies of a population of patients with MR, we show that selective serotonin reuptake inhibitor (SSRI) use and &lt;i>SERT&lt;/i> promoter polymorphism 5-HTTLPR LL genotype were associated with MV surgery at younger age. Functional characterization of 122 human MV samples, in conjunction with in vivo studies in &lt;i>SERT&lt;/i>&lt;sup>-/-&lt;/sup> mice and wild-type mice treated with the SSRI fluoxetine, showed that diminished SERT activity in MV interstitial cells (MVICs) contributed to the pathophysiology of MR through enhanced serotonin recepto</pubmed_abstract><journal>Science translational medicine</journal><pubmed_title>Decreased serotonin transporter activity in the mitral valve contributes to progression of degenerative mitral regurgitation.</pubmed_title><pmcid>PMC9896655</pmcid><funding_grant_id>R01 HL131872</funding_grant_id><funding_grant_id>P30 CA013696</funding_grant_id><pubmed_authors>Nissim I</pubmed_authors><pubmed_authors>Pressly BB</pubmed_authors><pubmed_authors>Oyama MA</pubmed_authors><pubmed_authors>Ferrari G</pubmed_authors><pubmed_authors>Simpson MT</pubmed_authors><pubmed_authors>D'Angelo AM</pubmed_authors><pubmed_authors>Camillo C</pubmed_authors><pubmed_authors>Brown C</pubmed_authors><pubmed_authors>Krieger AM</pubmed_authors><pubmed_authors>Castillero E</pubmed_authors><pubmed_authors>Salvati E</pubmed_authors><pubmed_authors>Aghali A</pubmed_authors><pubmed_authors>Keeney SJ</pubmed_authors><pubmed_authors>Moreno V</pubmed_authors><pubmed_authors>Levy RJ</pubmed_authors><pubmed_authors>Grau JB</pubmed_authors><pubmed_authors>Rauova L</pubmed_authors><pubmed_authors>Kurade M</pubmed_authors><pubmed_authors>Shukla HJ</pubmed_authors><pubmed_authors>Stachelek SJ</pubmed_authors><pubmed_authors>Fitzpatrick E</pubmed_authors><pubmed_authors>Inamdar VV</pubmed_authors><pubmed_authors>Erwin WC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Decreased serotonin transporter activity in the mitral valve contributes to progression of degenerative mitral regurgitation.</name><description>Degenerative mitral valve (MV) regurgitation (MR) is a highly prevalent heart disease that requires surgery in severe cases. Here, we show that a decrease in the activity of the serotonin transporter (SERT) accelerates MV remodeling and progression to MR. Through studies of a population of patients with MR, we show that selective serotonin reuptake inhibitor (SSRI) use and &lt;i>SERT&lt;/i> promoter polymorphism 5-HTTLPR LL genotype were associated with MV surgery at younger age. Functional characterization of 122 human MV samples, in conjunction with in vivo studies in &lt;i>SERT&lt;/i>&lt;sup>-/-&lt;/sup> mice and wild-type mice treated with the SSRI fluoxetine, showed that diminished SERT activity in MV interstitial cells (MVICs) contributed to the pathophysiology of MR through enhanced serotonin recepto</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-04T03:01:12.478Z</modification><creation>2025-04-04T03:01:12.478Z</creation></dates><accession>S-EPMC9896655</accession><cross_references><pubmed>36599005</pubmed><doi>10.1126/scitranslmed.adc9606</doi></cross_references></HashMap>